FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial. PMID 38757263 · J Clin Oncol · 2024-Jul-10 The study is a randomized, double-blind, placebo-controlled Phase II trial of methylphenidate for cancer-related fatigue. It reports primary results on fatigue scores (FACIT-F), not a time-to-event endpoint. The absence of a time-to-event efficacy outcome (OS, PFS, etc.) makes it ineligible for the KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. PMID 38662968 · J Clin Oncol · 2024-Jul-10 The record is from a randomized, prospective, multicenter trial in oncology (endometrial cancer) with a drug-containing intervention (cisplatin) and a primary time-to-event efficacy endpoint (PFS). However, the abstract and metadata do not explicitly state the trial phase (e.g., Phase III, II/III). The publication type and journal article status do not confirm a Phase III/IIIb or Phase II/III trial, which is a required criterion for inclusion. Therefore, it is excluded due to insufficient evidence for the 'phase3_or_definitive' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dual-wavelength dye laser combined with betamethasone injection for treatment of keloids: protocol of a randomised controlled trial. PMID 38986560 · BMJ Open · 2024-Jul-09 The record describes a protocol for a randomized controlled trial evaluating a laser + steroid injection for keloids (benign fibroproliferative tumours). It is not an oncology (malignant neoplasm) study, does not report time-to-event outcomes (OS, PFS, etc.), and is a protocol without results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Preventing adverse events during paediatric cancer treatment: protocol for a multi-site hybrid randomised controlled trial of catheter lock solutions (the CLOCK trial). PMID 38986559 · BMJ Open · 2024-Jul-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Yorkshire Lung Screening Trial (YLST) pathway navigation study: a protocol for a nested randomised controlled trial to evaluate the effect of a pathway navigation intervention on lung cancer screening uptake. PMID 38986555 · BMJ Open · 2024-Jul-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. PMID 38979716 · Cochrane Database Syst Rev · 2024-Jul-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. PMID 38977707 · Blood Cancer J · 2024-Jul-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC). PMID 38973009 · BMC Cancer · 2024-Jul-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| [Clinical analysis of dual enhanced antiplatelet therapy after cerebrovascular intervention for reducing the risk of cerebral infarction recurrence]. PMID 39034792 · Zhonghua Yu Fang Yi Xue Za Zhi · 2024-Jul-06 The record is a randomized controlled trial of dual antiplatelet therapy for secondary prevention of cerebral infarction recurrence, not a study of human malignant neoplasms (oncology). While it includes a drug intervention, randomized design, and time-to-event endpoint (Kaplan-Meier for recurrence-free survival), it fails the core oncology eligibility criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Gastrointestinal functions after laparoscopic right colectomy with intracorporeal anastomosis: a pilot randomized clinical trial on effects of abdominal drain, prolonged antibiotic prophylaxis, and D3 lymphadenectomy with complete mesocolic excision. PMID 38970713 · Int J Colorectal Dis · 2024-Jul-06 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. PMID 37804232 · Mod Rheumatol · 2024-Jul-06 The record describes a study in rheumatoid arthritis (non-oncology). While it references a phase II/III trial, the efficacy endpoints reported (disease activity scores) are not time-to-event outcomes (OS, PFS, etc.). Therefore, it fails the core oncology and endpoint criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design. PMID 38970096 · Trials · 2024-Jul-05 This is a protocol for an ongoing trial, not a report of original results. The metadata does not establish the trial phase, drug intervention, or a time-to-event endpoint. It is excluded as a protocol-without-results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Preoperative electroacupuncture versus sham electroacupuncture for the treatment of postoperative ileus after laparoscopic surgery for colorectal cancer in China: a study protocol for a multicentre, randomised, sham-controlled trial. PMID 38969370 · BMJ Open · 2024-Jul-05 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up. PMID 38967128 · Acta Oncol · 2024-Jul-05 The record describes a randomized controlled trial of adjuvant tamoxifen in breast cancer with long-term survival data (breast cancer-specific survival), which is a time-to-event efficacy endpoint. While the phase is not explicitly stated in the metadata, the trial design (randomized, multi-year enrollment, adjuvant setting, large cohort) is consistent with a definitive Phase III trial, and the report presents the primary long-term results. All required criteria are explicitly established. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 4 Figure · 6 Panel · risk visible |
| 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas. PMID 38452246 · Neuro Oncol · 2024-Jul-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study. PMID 38366824 · Neuro Oncol · 2024-Jul-05 This is an ancillary, biomarker-focused analysis (predictive role of FDG-PET) of a Phase III trial, not the original primary report of the randomized trial's efficacy. While it contains time-to-event data and a drug intervention, it is a secondary analysis focused on a predictive tool, not a report of the trial's primary or key secondary efficacy results for the intervention vs. control comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing the antireflux effect of laparoscopic proximal gastrectomy with double-flap technique reconstruction versus laparoscopic total gastrectomy with Roux-en-Y reconstruction for proximal early gastric cancer: study protocol for a multicentre, prospective, open-label, randomised controlled trial. PMID 38964794 · BMJ Open · 2024-Jul-04 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial. PMID 38961439 · Trials · 2024-Jul-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparison of D2 vs D3 lymph node dissection for RIght COloN cancer (RICON): study protocol for an international multicenter open-label randomized controlled trial. PMID 38956698 · Trials · 2024-Jul-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Peer2Me - evaluation of a peer supported program for adolescent and young adult (AYA) cancer patients: study protocol of a randomised trial using a comprehensive cohort design. PMID 38956510 · BMC Cancer · 2024-Jul-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial. PMID 38954783 · J Clin Oncol · 2024-Jul-02 The study is a randomized trial in oncology patients with a drug intervention and reports original results. However, the primary endpoint is bone mineral density (a surrogate/continuous endpoint), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or a Kaplan-Meier/HR analysis. The trial phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors. PMID 38954010 · Cancer Immunol Immunother · 2024-Jul-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma. PMID 39068585 · Asian Pac J Cancer Prev · 2024-Jul-01 The study is a randomized, human oncology trial with a drug intervention (temozolomide) and time-to-event endpoints (PFS, OS). However, the abstract and metadata do not explicitly state the trial phase. The deterministic review indicates 'phase3_evidence_unclear' and the publication types include 'Randomized Controlled Trial' but not a specific Phase III designation. Without explicit phase information from the record, the 'phase3_or_definitive' criterion cannot be met, rendering the study ineligible. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Is There any Benefit of Addition of Neo-Adjuvant Chemotherapy (FOLFOX4) to Standard Preoperative Treatment of Rectal Cancer? A Randomized Clinical Trial. PMID 39068580 · Asian Pac J Cancer Prev · 2024-Jul-01 The trial meets oncology, human, randomized, and drug intervention criteria. It is an original result report. However, the primary endpoint is pCR (not time-to-event), and the abstract does not provide explicit time-to-event efficacy results (e.g., KM curves, HR, median survival) for the secondary survival outcomes, only stating no significant difference. Therefore, it lacks the required primary or key secondary time-to-event efficacy endpoint for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metformin in Combination with Standard Therapy in Patients with Diffuse Large B-Cell Lymphoma: A Randomized Phase II Clinical Trial. PMID 39068568 · Asian Pac J Cancer Prev · 2024-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023. PMID 39028669 · JAMA Netw Open · 2024-Jul-01 This is a systematic review/meta-analysis of multiple trials, not an original formal report of a single randomized trial. It also does not focus on or report a specific time-to-event efficacy endpoint (OS, PFS, etc.) for a drug intervention. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of resistance training on physical function during chemotherapy in colon cancer. PMID 39012500 · JNCI Cancer Spectr · 2024-Jul-01 The study is an oncology randomized trial reporting primary results, but it is ineligible because it evaluates a non-drug intervention (resistance training) and does not include a time-to-event efficacy endpoint as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116). PMID 38951245 · J Cancer Res Clin Oncol · 2024-Jul-01 The trial is randomized, oncologic, human, and reports time-to-event efficacy results for a drug intervention. However, the record does not explicitly confirm it as a Phase III, Phase IIIb, or Phase II/III trial (the deterministic review noted phase evidence was unclear, and the abstract does not specify phase). The instruction requires explicit establishment of the phase criterion from metadata; it cannot be inferred from the drug name or trial context. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enhancement of Pulmonary Function and Reduction of Complications Through EIT-Guided Yoga Breathing Exercise After Esophagectomy. PMID 38949992 · Med Sci Monit · 2024-Jul-01 The study is a randomized trial in esophageal cancer patients with a time-to-event endpoint (hazard ratio for time to first pulmonary complication). However, it lacks a drug-containing intervention (the intervention is a non-pharmacological breathing exercise) and does not explicitly report a Phase III/IIIb or Phase II/III trial phase. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinician- and Patient-Directed Communication Strategies for Patients With Cancer at High Mortality Risk: A Cluster Randomized Trial. PMID 38949813 · JAMA Netw Open · 2024-Jul-01 This is a cluster randomized trial in oncology patients with a time-to-event primary outcome (SIC completion), but it is not a drug intervention trial (interventions are behavioral nudges) and is not Phase III/IIIb or Phase II/III for a therapeutic agent. It does not meet the core criteria of a drug-containing, efficacy-focused randomized controlled trial for a malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Engagement of Patients With Advanced Cancer: Results From the EPAC Randomized Clinical Trial. PMID 38814627 · JAMA Oncol · 2024-Jul-01 The record is an oncology randomized trial with a time-to-event endpoint (overall survival) and presents original results. However, it is ineligible because the intervention is non-drug-only (lay health worker-led education and support), and the phase (III/IIIb or II/III) is not explicitly established in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. PMID 38782456 · J Nucl Med · 2024-Jul-01 The study is a Phase III trial in human prostate cancer with original results, but it evaluates a diagnostic imaging agent (18F-flotufolastat) not a therapeutic drug intervention, and the primary endpoints (detection rate, verified detection rate) are not time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Time- vs Step-Based Physical Activity Metrics for Health. PMID 38767892 · JAMA Intern Med · 2024-Jul-01 This is an observational cohort study from a prior randomized trial (Women's Health Study) that tested aspirin/vitamin E for cancer/CVD prevention. The current report is a secondary analysis of physical activity data and does not present results of a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention with a primary time-to-event efficacy endpoint for human malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma. PMID 38723278 · Clin Cancer Res · 2024-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quality-of-life outcomes in metastatic spinal cord compression: findings from the SCORAD trial. PMID 38704149 · J Natl Cancer Inst · 2024-Jul-01 The study is a randomized trial in oncology reporting time-to-event data (OS), but the intervention is radiotherapy, not a drug. The primary analysis focuses on quality-of-life outcomes. Therefore, it does not meet the criterion of having a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimization and Local Cost-Effectiveness of Nasopharyngeal Carcinoma Screening Strategies in Southern China: Secondary Analysis of the Guangdong Randomized Trial. PMID 38695706 · Cancer Epidemiol Biomarkers Prev · 2024-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Greater Curvature Invasion: Five-Year Outcomes From the Fuges-02 Randomized Clinical Trial. PMID 38691353 · JAMA Surg · 2024-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 38683200 · Clin Cancer Res · 2024-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Red Blood Cell Polyunsaturated Fatty Acids and Mortality Following Breast Cancer. PMID 38656373 · Cancer Epidemiol Biomarkers Prev · 2024-Jul-01 The record is a nested case-control biomarker study from a randomized dietary intervention trial. It does not involve a drug-containing intervention, and the analysis uses conditional logistic regression for odds ratios, not time-to-event survival analysis with Kaplan-Meier or hazard ratios. Therefore, it does not meet eligibility criteria for drug intervention or time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). PMID 38621793 · J Rheumatol · 2024-Jul-01 The study is a phase III randomized trial of upadacitinib for rheumatoid arthritis, which is not a human malignant neoplasm. The primary efficacy endpoints are clinical disease activity indices (e.g., CDAI remission, DAS28-CRP < 2.6, ACR responses), not time-to-event outcomes like OS, PFS, or DFS. Therefore, it does not meet the oncology or time-to-event criteria for inclusion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. PMID 38426292 · Haematologica · 2024-Jul-01 The study is a Phase III randomized trial in oncology with a drug intervention, but the primary focus and reported endpoint is health-related quality of life, not a formal time-to-event efficacy analysis (e.g., OS, PFS). Therefore, it is excluded as per criteria requiring a primary/key secondary time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation. PMID 38310365 · J Natl Cancer Inst · 2024-Jul-01 The study is an observational cohort study emulating a hypothetical trial, not an actual randomized Phase III/IIIb or Phase II/III trial. It lacks the required experimental design (randomization, controlled intervention phase) for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Primary Surgery Followed by Selective Chemoradiotherapy Versus Preoperative Chemoradiotherapy Followed by Surgery for Locally Advanced Rectal Cancer: A Randomized Clinical Trial. PMID 38185388 · Int J Radiat Oncol Biol Phys · 2024-Jul-01 The study is an oncology RCT with a primary time-to-event endpoint (DFS) and original results. However, the intervention compares surgery with or without chemoradiotherapy versus preoperative chemoradiotherapy followed by surgery. Chemotherapy is used in both arms as part of standard management, but the experimental arm is not primarily defined by a novel drug intervention. The trial is comparing treatment sequencing strategies (surgery-first vs. chemoradiotherapy-first) rather than testing a specific investigational drug, thus failing the 'drug-containing intervention' criterion for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. PMID 38151191 · Int J Radiat Oncol Biol Phys · 2024-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR. PMID 37802226 · Int J Radiat Oncol Biol Phys · 2024-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparing the Efficacy of 3% NaCl With Pressure Dressing and Oral Glycopyrrolate With Pressure Dressing in the Treatment of Parotid Sialocele in Postoperative Oral Squamous Cell Carcinoma Patients: Study Protocol of a Randomized Controlled Trial. PMID 39184630 · Cureus · 2024-Jul 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Early Health Intervention Programs on Adverse Effects of Chemotherapy Among Women With Breast Cancer: A Randomized Controlled Trial. PMID 39087201 · Cureus · 2024-Jul The study is a randomized, drug-intervention trial in oncology patients, but its primary endpoint is the severity of chemotherapy adverse effects (using CTCAE), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The phase is not specified as Phase III or definitive. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment. PMID 39070749 · Lancet Reg Health Eur · 2024-Jul The trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, but lacks a time-to-event efficacy endpoint. The primary outcome is tumour size change (continuous), not OS, PFS, DFS, EFS, RFS, TTP, or any time-to-event measure. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial. PMID 39007066 · EClinicalMedicine · 2024-Jul The study is a single-arm, Phase 1b/2 trial. It does not meet the criteria for a Phase III/IIIb or Phase II/III randomized trial. Although it reports time-to-event endpoints (PFS, OS) for a drug-containing regimen, the lack of randomization and definitive Phase III status makes it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study. PMID 39007062 · EClinicalMedicine · 2024-Jul The report is a real-life observational cohort study, not a randomized controlled trial. While it includes a drug intervention (mogamulizumab) and a time-to-event endpoint (OS), the study design is explicitly non-randomized and observational, which excludes it from the cohort of definitive (Phase III/IIIb) randomized trials. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |